



(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 491/107 (2006.01)
C07D 405/14 (2006.01) C07D 498/08 (2006.01)
C07D 407/14 (2006.01) C07D 498/10 (2006.01)
C07D 411/14 (2006.01) C07D 513/04 (2006.01)
C07D 415/00 (2006.01) A61P 3/10 (2006.01)
C07D 471/04 (2006.01) A61P 21/00 (2006.01)
C07D 487/04 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2024/070617

(22) International Filing Date:

19 July 2024 (19.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2311227.9 21 July 2023 (21.07.2023) GB

(71) Applicant: **ALMAC DISCOVERY LIMITED** [GB/GB];
Almac House, 20 Seagoe Industrial Estate, Craigavon BT63
5QD (GB).

(72) Inventors: **HELM, Matthew Duncan**; c/o Almac House,
20 Seagoe Industrial Estate, Craigavon BT63 5QD (GB).
TREDER, Adam Piotr; c/o Almac House, 20 Seagoe In-
dustrial Estate, Craigavon BT63 5QD (GB). **ROUNTREE,**
James Samuel Shane; c/o Almac House, 20 Seagoe Indus-
trial Estate, Craigavon BT63 5QD (GB). **MCFARLAND,**
Mary; c/o Almac House, 20 Seagoe Industrial Estate,
Craigavon BT63 5QD (GB). **SHEPHERD, Steven David**;
c/o Almac House, 20 Seagoe Industrial Estate, Craigavon
BT63 5QD (GB). **SALEWSKA, Natalia Wanda**; c/o Al-
mac House, 20 Seagoe Industrial Estate, Craigavon BT63
5QD (GB). **BURKAMP, Frank**; c/o Almac House, 20 Sea-
goe Industrial Estate, Craigavon BT63 5QD (GB).

(74) Agent: **BOULT WADE TENNANT LLP**; Salisbury
Square House, 8 Salisbury Square, London EC4Y 8AP
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) Title: PHARMACEUTICAL COMPOUNDS





Figure 1



(57) **Abstract:** The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.

[Continued on next page]

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*